Glutamate and schizophrenia: phencyclidine, N‐methyl‐d‐aspartate receptors, and dopamine–glutamate interactions

DC Javitt - International review of neurobiology, 2007 - Elsevier
Schizophrenia is a serious mental disorder that affects up to 1% of the population worldwide.
As of yet, neurochemical mechanisms underlying schizophrenia remain unknown. To date …

[HTML][HTML] Amino acid transporters as targets for cancer therapy: why, where, when, and how

S Bröer - International journal of molecular sciences, 2020 - mdpi.com
Amino acids are indispensable for the growth of cancer cells. This includes essential amino
acids, the carbon skeleton of which cannot be synthesized, and conditionally essential …

Glutamate as a therapeutic target in psychiatric disorders

DC Javitt - Molecular psychiatry, 2004 - nature.com
Glutamate is the primary excitatory neurotransmitter in the mammalian brain. Glutamatergic
neurotransmission may be modulated at multiple levels, only a minority of which are …

[PDF][PDF] Glutamatergic theories of schizophrenia

DC Javitt - Israel Journal of Psychiatry, 2010 - cdn.doctorsonly.co.il
Schizophrenia is a serious mental disorder that affects up to 1% of the population worldwide.
traditional models of schizophrenia have emphasized dopaminergic dysfunction. over the …

Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain

RJ Harvey, BK Yee - Nature reviews Drug discovery, 2013 - nature.com
Glycine transporters are endogenous regulators of the dual functions of glycine, which acts
as a classical inhibitory neurotransmitter at glycinergic synapses and as a modulator of …

Glycine transporters: essential regulators of neurotransmission

V Eulenburg, W Armsen, H Betz, J Gomeza - Trends in biochemical …, 2005 - cell.com
Glycine has important neurotransmitter functions at inhibitory and excitatory synapses in the
vertebrate central nervous system. The effective synaptic concentrations of glycine are …

Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia

SP Singh, V Singh - CNS drugs, 2011 - Springer
Background: Based on the glutamatergic NMDA receptor hypofunction theory of
schizophrenia, NMDA receptor modulators (NMDARMs) may have therapeutic potential in …

N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

MJ Millan - Psychopharmacology, 2005 - Springer
Rationale Activation of “co-agonist” N-methyl-d-aspartate (NMDA) and Glycine B sites is
mandatory for the operation of NMDA receptors, which play an important role in the control …

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

RW Buchanan, R Freedman, DC Javitt… - Schizophrenia …, 2007 - academic.oup.com
Wayne Fenton was a major driving force behind the establishment of the Measurement and
Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units …

[HTML][HTML] Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of …

R Depoortère, G Dargazanli… - …, 2005 - nature.com
Noncompetitive N-methyl-D-aspartate (NMDA) blockers induce schizophrenic-like
symptoms in humans, presumably by impairing glutamatergic transmission. Therefore, a …